Vigil Neuroscience announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer. Dr. Kaufmann succeeds Christopher Silber, M.D. Dr. Kaufmann is an accomplished biotech executive joining Vigil Neuroscience from Affinia Therapeutics where she served as Chief Medical Officer leading medical, clinical, patient advocacy and regulatory strategy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VIGL:
- Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
- VIGL Earnings this Week: How Will it Perform?
- Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
- Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
- Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
